Aerie Pharmaceuticals

Aerie Pharmaceuticals (NASDAQ: AERI) is a publicly traded, clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye. Aerie's two lead product candidates are once-daily IOP-lowering therapies with novel mechanisms of action to treat patients with glaucoma or ocular hypertension.[1][2][3]

References

  1. ↑ Witkowski, Wallace (16 September 2015). "Aerie Pharma Shares Skyrocket On Glaucoma Drug Study Results". Fox Business.
  2. ↑ Beckerman, Josh. "Aerie Pharmaceuticals Shares Rise on Trial Results". Wall Street Journal.
  3. ↑ "Aerie Pharma shares battered as eye drug fails study". Reuters. 23 April 2015. Retrieved 7 January 2016.

External links

This article is issued from Wikipedia - version of the 9/22/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.